This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg real-world evidence

Real-world outcomes in previously treated patients with nAMD after three initial doses of EYLEA 8 mg

NHS Greater Glasgow and Clyde

These data are from real patients. Individual results may vary.

Study design:
Retrospective study evaluated outcomes in 39 previously treated eyes with nAMD. Outcomes evaluated were visual acuity, central foveal thickness, fluid status and treatment intervals.

Patients received three initial doses of EYLEA 8 mg at matched intervals (three doses on q8 or q12 intervals); thereafter, planned treatment protocol was at clinician discretion.
Patients were followed up to after initial three doses of EYLEA 8 mg at matched intervals.

Patient demographics	
Eyes, N	39
Mean age, years	79
Female, %	51

Previous anti-VEGF treatment (N=39)



Fluid control with EYLEA 8 mg

Fluid status over time†



After three doses of EYLEA 8 mg*,‡

IRF	SRF	SRF and IRF
↓ 28.2%	↓ 10.2%	↓ 15.4%

Change in the proportion of eyes with fluid (N=39)

*After initial three doses of EYLEA 8 mg at matched intervals. †Percentage values may not add up to 100 due to rounding. ‡Calculated reductions in percentage are changes relative to the whole population, and not the percentage reduction of each subpopulation for each parameter.

Abbreviations:
IRF, intraretinal fluid; **nAMD**, neovascular age-related macular degeneration; **q8,** every 8 weeks; **q12,** every 12 weeks; **SRF**, subretinal fluid; **VEGF**, vascular endothelial growth factor.

Reference:
Bayer UK Data on File_ PP-EYL_8mg-GB-0899_January 2026.

May 2026 | PP-EYL_8mg-GB-1043

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

Longer treatment intervals with EYLEA 8 mg
vs. previous anti-VEGF treatment

Interval prior to switch



Planned interval after three doses of EYLEA 8 mg



Maintained vision with EYLEA 8 mg

Change in VA over time



+1 ETDRS letters

Mean change in VA after switching to EYLEA 8 mg (N=39)

Maintained fluid control with EYLEA 8 mg

Change in CFT over time



–39 µm

Mean change in CFT after switching to EYLEA 8 mg (N=39)

No adverse events were reported in this audit with EYLEA 8 mg

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
*No further injections planned but patients monitored in clinic. †Patient care transferred to another centre; this was unrelated to anti-VEGF treatment. ‡After initial three doses of EYLEA 8 mg at matched intervals.

Abbreviations:
CFT, central foveal thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **qX**, every X weeks; **VA**, visual acuity; **VEGF**, vascular endothelial growth factor.

Reference:
Bayer UK Data on File_ PP-EYL_8mg-GB-0899_January 2026.

May 2026 | PP-EYL_8mg-GB-1043

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.